NCT00551707View on ClinicalTrials.gov

Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

January 31, 2009

Conditions

Rheumatoid Arthritis

Interventions

DRUG

CRx-102 (2.7/180)

prednisolone 2.7 mg plus dipyridamole 180 mg

DRUG

prednisolone

prednisolone (2.7 mg)

DRUG

dipyridamole

dipyridamole 360 mg

DRUG

placebo

placebo

DRUG

CRx-102 (2.7/360)

Prednisolone 2.7 mg plus Dipyridamole 360 mg

Trial Locations (48)

Unknown

Birmingham

Huntsville

Phoenix

Little Rock

Anaheim

La Jolla

Westlake Village

Palm Harbor

Elizabethtown

Haddon Heights

Mayfield Village

Oklahoma City

Dallas

Buenos Aires

Rosario

San Jan

San Miguel de Tucumán

Winnipeg

St. John's

Hamilton

Windsor

Tallinn

Tartu

Békéscsaba

Esztergom

Szolnok

Kaunas

Vilnius

Aguascalientes

Vallarta Norte

Bialystok

Elblag

Katowice

Krakow

Lublin

Poznan

Torun

Warsaw

Bucharest

Cluj-Napoca

Timișoara

Moscow

Saint Petersburg

Belgrade

Niška Banja

Pretoria

Cape Town

Worcester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Zalicus

INDUSTRY

NCT00551707 - Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter